^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tazverik (tazemetostat)

    i
    Other names: EZM6438, IPN60200, EPZ-6438, E7438, EZ-438, E 7438, E-7438, EPZ6438, EPZ 6438, EZ438, EZ 438, EZM-6438, EZM 6438, IPN-60200, IPN 60200
    Company:
    Eisai, Hutchmed, Ipsen, Royalty
    Drug class:
    EZH2 inhibitor
    Related drugs:
    2d
    A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tazverik (tazemetostat) • AiRuiEn (rezvilutamide) • HRS-5041
    3d
    SYMPHONY-1: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (clinicaltrials.gov)
    P3, N=555, Active, not recruiting, Epizyme, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Feb 2027
    Enrollment closed • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    6d
    Study of Tazemetostat in Lymphoid Malignancies (clinicaltrials.gov)
    P1, N=6, Terminated, University of Alabama at Birmingham | N=30 --> 6 | Trial completion date: Dec 2029 --> Mar 2026 | Recruiting --> Terminated | Trial primary completion date: Jul 2028 --> Mar 2026; Ipsen, drug company requested all studies using the drug Taxemetostat be terminated due to increased risk of secondary malignancies in subjects.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Tazverik (tazemetostat)
    7d
    A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (clinicaltrials.gov)
    P1, N=18, Terminated, Epizyme, Inc. | Completed --> Terminated; Ipsen decided to discontinue all active tazemetostat clinical trials.
    Trial termination
    |
    Tazverik (tazemetostat)
    8d
    A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (clinicaltrials.gov)
    P1, N=18, Completed, Epizyme, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Tazverik (tazemetostat)
    10d
    TAZNI: Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Susan Chi, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)
    11d
    Study on the inhibition of thyroid undifferentiated carcinoma metastasis by nanoparticles loaded with EZH2 inhibitor. (PubMed, Transl Cancer Res)
    EZH2 is highly expressed in ATC, and its inhibitors EPZ6438 and GSK343 have anti-cancer potential. Two types of nanoparticles were successfully constructed with good sustained-release, targeting effects, and biosafety. They could improve the therapeutic efficacy and reduce toxic side effects, with GSK343-BSA@CS showing significant effects.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    Tazverik (tazemetostat) • GSK343
    17d
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Suspended, University of Utah | Recruiting --> Suspended
    Trial suspension
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)
    17d
    A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (clinicaltrials.gov)
    P1, N=18, Terminated, Epizyme, Inc. | Recruiting --> Terminated; Ipsen decided to discontinue all active tazemetostat clinical trials.
    Trial termination
    |
    Tazverik (tazemetostat)
    21d
    Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=3, Terminated, Weill Medical College of Cornell University | N=38 --> 3 | Trial completion date: Dec 2028 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Feb 2026; Low accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Venclexta (venetoclax) • Tazverik (tazemetostat)
    21d
    Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | N=50 --> 23
    Enrollment closed • Enrollment change
    |
    EZH2 mutation
    |
    Tazverik (tazemetostat) • Lunsumio (mosunetuzumab-axgb)
    30d
    Epithelioid sarcoma: from SMARCB1 loss to therapeutic vulnerabilities. (PubMed, Curr Opin Oncol)
    Despite progress in understanding ES biology, treatment options are limited, and prognosis remains poor. Further studies are needed, but the rarity of the disease limits opportunities for conducting dedicated clinical trials or broader molecular characterization.
    Journal
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Tazverik (tazemetostat)